| abstract |
Disclosed is the use of an active ingredient in the manufacture of a medicament, wherein the active ingredient is selected from the group consisting of butylidenephthalide (BP), a pharmaceutically acceptable salt thereof, and a combination thereof, and wherein the medicament is used for the prevention and/or treatment of oral submucous fibrosis (OSF) and may be used in the form of a injection, lozenge, oral solution, or smearing preparation. |